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Introduction: The treatment of hypertension in older people was controversial until results from the 
HYpertension in the Very Elderly Trial (HYVET) demonstrated benefit in those 80 years or older. 
The HYVET ambulatory blood pressure (BP) sub study analysis of a small representative sample 
reported up to 60% of patients in the main study may have had white coat hypertension (WCH) [1], 
defined as clinic BP readings ≥140/90 mmHg and ambulatory BP readings <135/85 mmHg. 
Currently treatment is not recommended for such individuals.  
This study serves as a prelude to a definitive randomised controlled trial (HYVET 2) to determine 
whether the treatment of WCH in the very elderly is feasible and outweighs any adverse events. 
 
Methods: Open-label study assessing the feasibility of a randomised controlled trial to treat WCH 
in primary care in 100 patients aged ≥75 years with equal randomisation to a treatment arm 
(indapamide and perindopril) and control arm (no treatment). Recruitment from May 2018; 52 
weeks’ follow up. 
 
Results: Will report patient recruitment, adherence and withdrawal rates, willingness of GPs to 
recruit and randomise patients and the frequency of a composite of cardiovascular events.  
 
Conclusions: It is unknown whether older adults with WCH benefit from treatment. This feasibility 
study will inform the planning of a definitive trial in an attempt to address this research question. 
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